Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

LAF-237 (Novartis).

Daniela Barlocco1

  • 1University of Milan, Istituto di Chimica Farmaceutica e Tossicologica, Viale Abruzzi 42, 20131 Milano, Italy. daniela.barlocco@unimi.it

Current Opinion in Investigational Drugs (London, England : 2000)
|November 13, 2004
PubMed
Summary

Novartis is developing LAF-237, a new oral medication for type 2 diabetes. This dipeptidylpeptidase IV inhibitor is being tested in Phase III clinical trials for once-daily use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel Antibacterial Agents 2022.

Pharmaceuticals (Basel, Switzerland)·2024
Same author

Selective Inhibitors of Histone Deacetylase 10 (HDAC-10).

Current medicinal chemistry·2021
Same author

Special Issue "Novel Antibacterial Agents".

Pharmaceuticals (Basel, Switzerland)·2021
Same author

Synthesis, Characterization, and Biological Evaluation of New Derivatives Targeting MbtI as Antitubercular Agents.

Pharmaceuticals (Basel, Switzerland)·2021
Same author

Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.

Current medicinal chemistry·2020
Same author

New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agents.

Journal of enzyme inhibition and medicinal chemistry·2019

Area of Science:

  • Pharmacology
  • Endocrinology
  • Drug Development

Background:

  • Type 2 diabetes is a growing global health concern.
  • Current treatments for type 2 diabetes have limitations.
  • Novel therapeutic agents are needed to improve glycemic control.

Purpose of the Study:

  • To evaluate LAF-237, an orally active dipeptidylpeptidase IV inhibitor, as a potential treatment for type 2 diabetes.
  • To assess the efficacy and safety of once-daily administration of LAF-237.

Main Methods:

  • Development of LAF-237, an orally active dipeptidylpeptidase IV inhibitor.
  • Initiation of Phase III clinical trials in Q1 2004.

Main Results:

  • LAF-237 demonstrated potential as a therapeutic agent for type 2 diabetes.
  • Further clinical data from Phase III trials are pending.

Conclusions:

  • LAF-237 represents a promising new class of oral agents for type 2 diabetes management.
  • Once-daily dosing may improve patient compliance and therapeutic outcomes.

Related Experiment Videos